x

Like our Facebook Page

   
Early Times Newspaper Jammu, Leading Newspaper Jammu
 
Breaking News :   Omar intervenes to thwart political exploitation of reservation protests | CM quotes Rudyard Kipling | Tara Chand skips Madan Lal Sharma’s death anniversary event | Winter vacation in High Court from Jan 6 | Follow traffic advisory: MeT tells tourists | Centre scraps no-detention policy | SIA cracks down on ‘Kashmir Fight’ terror threats targeting migrant KP employees | LG Inaugurates IGNCA Regional Centre at Jammu, emphasizes promotion of art & culture | Face covering by women advocates violates BCI dress code: J&K High Court | Record Govt jobs provided in 1.5 years: PM Modi | DDC Chairman Bharat Bhushan Rebukes Haseeb Drabu’s Critique of DDCs | KVIB Ramban organises awareness program at ITI Kawbagh | Bus Stand Police Jammu reunites missing girl with family | Vision document 2047 finalized for District Poonch | Rozgar Mela | Mahakumbh: An opportunity for Prayagraj to shine in hospitality, says CM Yogi | Quality education imperative for honing intellectual capacity of youth: Dy CM | Business leader Rahul Sahai honored in Georgia | Sr BJP leader Ghulam Ali Khatana visits Darul Uloom Deoband | JMC, police conduct joint anti encroachment drive | Encouragement to investment prime focus of J&K bank | Kathua Admin announces ex-gratia relief for families affected by fire incident | HC deny bail to Army Major in dowry death case | Grand celebration of Kisan Diwas held at Directorate of Horticulture Jammu | KVK Reasi celebrates National Farmers Day | PIB Jammu organises seminar, bike rally to promote WAVES | Caste-based Census must for upliftment of society: Tony | NZIEA celebrates 69th Foundation Day Across J&K | Dr Virendra Kumar visits senior citizen home in Srinagar | Radha Soami Satsang Beas considers relocation of Bhota Hospital to Jammu region | Samba police trace missing minor girl | Hakla praised Ajaz Asad Administrative Secretary RDD | JSS Kathua Shines at CBSE National Adolescent Summit 2024 | Dogri Manyta Diwas celebrates at GCW Udhampur | SMVDU showcases excellence at Jammu Mahotsav 2024 | Desh Bhagat University's School of Nursing hosts Grand Freshers' Party | IDPS celebrates Annual Day "Wings of Change" | Dewan Devi Public School celebrates Christmas | Residential refresher coaching camp commences | Department of Dogri celebrates Dogri Manyata Divas | GDC Akhnoor celebrates Dogri Manta Divas | GDC Nagrota hosts awareness camp | GCW Bhagwati Nagar hosts thrilling Intra-College Kho-Kho match | Back Issues  
 
news details
Biocon recalls 3,665 bottles of antifungal drug in US for "Failed Specifications"
2/18/2023 11:03:16 PM
agencies
NEW DELHI, Feb 18: Biotechnology major Biocon is recalling 3,665 bottles of antifungal medication in the US market for "failed degradation specifications", according to the US Food and Drug Administration (USFDA).
In its latest Enforcement Report, the US health regulator said that the Bengaluru-based firm is recalling 3,665 bottles of Posaconazole Delayed-Release Tablets (100 mg, 60-count bottle), used to treat serious fungal infections like invasive aspergillosis.
USFDA noted that the New Jersey-based Biocon Pharma Inc is recalling the affected lot due to "Failed Impurities/Degradation Specifications: High Out Of Specification degradation results." The lot has been manufactured by Biocon Pharma and distributed in the US by Iselin-based Biocon Pharma Inc, it added.
Biocon initiated the Class II nationwide (US) recall on January 31, this year.
As per the USFDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
On February 12, Biocon stated that the USFDA has issued a Complete Response Letter (CRL) for the biologics licence application filed for Bevacizumab by its partner Viatris.
The USFDA issues a CRL to convey to a company that its initial review of an application is complete and it cannot approve the application in its present form.
Earlier on January 7, the company had stated that the USFDA has issued a complete response letter for Biocon Biologics' application for Insulin-R, a proposed biosimilar for diabetes treatment.
  Share This News with Your Friends on Social Network  
  Comment on this Story  
 
 
 
Early Times Android App
STOCK UPDATE
  
BSE Sensex
NSE Nifty
 
CRICKET UPDATE
 
 
 
 
 
 
 
 
   
Home About Us Top Stories Local News National News Sports News Opinion Editorial ET Cetra Advertise with Us ET E-paper
 
 
J&K RELATED WEBSITES
J&K Govt. Official website
Jammu Kashmir Tourism
JKTDC
Mata Vaishnodevi Shrine Board
Shri Amarnath Ji Shrine Board
Shri Shiv Khori Shrine Board
UTILITY
Train Enquiry
IRCTC
Matavaishnodevi
BSNL
Jammu Kashmir Bank
State Bank of India
PUBLIC INTEREST
Passport Department
Income Tax Department
JK CAMPA
JK GAD
IT Education
Web Site Design Services
EDUCATION
Jammu University
Jammu University Results
JKBOSE
Kashmir University
IGNOU Jammu Center
SMVDU